GGrantIndex
Sort

50,496 grants matching lung cancer

Project 3: Identifying transcriptional driver genes and targeting transcription in TSC

$492,594
David J. Kwiatkowski · Brigham And Women'S Hospital · P01 · FY2021 · CA

Modeling Susceptibility to Chemotherapy-Induced Cardiotoxicity Using Human iPSCs

$492,582
Joseph C Wu · Stanford University · R01 · FY2017 · HL

Modeling Susceptibility to Chemotherapy-Induced Cardiotoxicity Using Human iPSCs

$492,582
Joseph C Wu · Stanford University · R01 · FY2016 · HL

Modeling Susceptibility to Chemotherapy-Induced Cardiotoxicity Using Human iPSCs

$492,582
Joseph C Wu · Stanford University · R01 · FY2014 · HL

Toward precision radiotherapy: Physiological modeling of respiratory motion based on ultra-quality 4D-MRI

$492,567
G. Wilson Miller · University Of Virginia · R01 · FY2019 · CA

Tribally Engaged Approaches to Lung Screening (TEALS)

$492,561
Zsolt J Nagykaldi · University Of Oklahoma Hlth Sciences Ctr · R01 · FY2020 · CA

The Women's Health Study: Addition of New Data to Maximize its Research Impact

$492,524
Julie E Buring · Brigham And Women'S Hospital · RC1 · FY2010 · HL

Interaction of histamine-releasing factor with immunoglobulins in asthma

$492,522
Toshiaki Kawakami · La Jolla Institute For Immunology · R01 · FY2014 · HL

A novel preclinical model of spontaneous metastasis

$492,427
Glenn T. Merlino · Division Of Basic Sciences - Nci · ZIA · FY2013 · CA

Mechanisms of enhancer regulation in leukemia

$492,409
Iannis Aifantis · New York University School Of Medicine · R01 · FY2022 · CA

Mechanisms of enhancer regulation in leukemia

$492,409
Iannis Aifantis · New York University School Of Medicine · R01 · FY2023 · CA

Simultaneous dose and dose rate optimization for clinical FLASH proton radiotherapy

$492,387
Hao Gao · Ut Southwestern Medical Center · R01 · FY2025 · CA

Extracellular Vesicles in Small Cell Lung Cancer Early Detection

$492,386
Serge P Nana-Sinkam · Virginia Commonwealth University · U01 · FY2020 · CA

TGF-beta for Pleurodesis

$492,336
Cumberland Pharmaceuticals, Inc. · R42 · FY2004 · HL

Efficacy and mechanisms of a behavioral therapy for insomnia coexisting with COPD

$492,323
Mary C Kapella · University Of Illinois At Chicago · R01 · FY2015 · NR

Nanoscintillator-based X-ray sensitizers to enable efficient NSCLC treatment with X-ray irradiation

$492,320
Jin Xie · University Of Georgia · R01 · FY2017 · EB

Crosstalk Between Metabolism and Inflammation in Pulmonary Hypertension

$492,243
Kurt R Stenmark · University Of Colorado Denver · R01 · FY2015 · HL

Phase I/II clinical evaluation of ABTL0812, a novel PI3K/Akt/mTOR inhibitor, with a unique mechanism of action inpancreatic cancer (Protocol sent on 20th June 2019 as an amendment of the IND 137394)

$492,233
Davendra Sohal · University Of Cincinnati · R01 · FY2023 · FD

Mechanisms of STING in malignant progression and therapy of CLL.

$492,142
Chih-Chi Andrew Hu · Methodist Hospital Research Institute · R01 · FY2025 · CA

Mechanisms of STING in malignant progression and therapy of CLL.

$492,142
Chih-Chi Andrew Hu · Methodist Hospital Research Institute · R01 · FY2023 · CA

EZH2 in cancer biology and novel inhibitors

$492,047
Jun Qi · Dana-Farber Cancer Inst · R01 · FY2019 · CA

CELL AND VECTOR PRODUCTION

$492,025
Helen E Heslop · Baylor College Of Medicine · P01 · FY2017 · CA

Synergistic combination of Proteolysis Targeting Chimera with a translational formulation for the treatment of intractable lung carcinoma

$492,000
Ketankumar D. Patel · St. John'S University · R15 · FY2023 · CA

Targeting Casein Kinase 1d/e (CK1d/1e) in Cancer Therapeutics

$491,992
William R Roush · Scripps Florida · R01 · FY2016 · CA

Targeting Casein Kinase 1d/e (CK1d/1e) in Cancer Therapeutics

$491,992
William R Roush · Scripps Florida · R01 · FY2015 · CA